Skip to main
ANIK
ANIK logo

Anika Therapeutics (ANIK) Stock Forecast & Price Target

Anika Therapeutics (ANIK) Analyst Ratings

Based on 7 analyst ratings
Hold
Strong Buy 14%
Buy 29%
Hold 43%
Sell 0%
Strong Sell 14%

Bulls say

Anika Therapeutics reported a sequential growth of 40% in surgical procedures, indicating a robust increase in demand for its orthopedic products, particularly its innovative patch technology. The company's revenue reached $30.6 million, reflecting a 1.4% year-over-year increase when adjusted for recent divestitures, while international revenue from osteoarthritis pain management grew by 22% in the quarter. Additionally, Anika raised its free cash flow target from $50 million to over $125 million due to improved working capital and operational efficiencies, reinforcing a positive outlook for the company's financial health and growth potential.

Bears say

Anika Therapeutics Inc has shown disappointing financial guidance for FY/25, as management has materially reduced its adjusted EBITDA margin estimate from a previously anticipated double-digit margin to a range of 8-10%. This revision primarily stems from pricing weakness in the U.S. market for osteoarthritis pain management, which has negatively impacted revenue expectations. Additionally, the potential adverse effects of pandemics and changes in consumer sentiment could further hinder sales, prompting a reduction in the 2025 adjusted EBITDA estimate from $12.5 million to $9.3 million.

Anika Therapeutics (ANIK) has been analyzed by 7 analysts, with a consensus rating of Hold. 14% of analysts recommend a Strong Buy, 29% recommend Buy, 43% suggest Holding, 0% advise Selling, and 14% predict a Strong Sell.

This aggregate rating is based on analysts' research of Anika Therapeutics and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Anika Therapeutics (ANIK) Forecast

Analysts have given Anika Therapeutics (ANIK) a Hold based on their latest research and market trends.

According to 7 analysts, Anika Therapeutics (ANIK) has a Hold consensus rating as of Jun 16, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $37.57, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $37.57, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Anika Therapeutics (ANIK)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.